GlycoEra leverages its control over natural glycan-mediated pathways to advance novel drugs using its propriety platform, the CustumGlycan Platform. GlycoEra develops first in class therapeutics in inflammatory disease, autoimmune disorder and immuno-oncology indications.

Location

Grabenstrasse 3, 8952 Schlieren, Zürich, Switzerland

Facts & figures
  • Type of organization

    Private company

  • Year of foundation

    2020

  • Number of employees in Switzerland

    10-19